Sorafenib‑based therapy in HER2‑negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials

Tan,Qi‑Xing; Qin,Qing‑Hong; Lian,Bin; Yang,Wei‑Ping; Wei,Chang‑Yuan

doi:10.3892/etm.2014.1603

Sorafenib‑based therapy in HER2‑negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials

Authors:
- Qi‑Xing Tan
- Qing‑Hong Qin
- Bin Lian
- Wei‑Ping Yang
- Chang‑Yuan Wei
View Affiliations

Affiliations: Breast Surgery Department, Tumor Hospital, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: March 5, 2014 https://doi.org/10.3892/etm.2014.1603
Pages: 1420-1426

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A standard systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)‑negative advanced breast cancer (ABC) is yet to be identified. Sorafenib has been developed for the treatment of solid tumors, including breast cancer, as an oral multikinase inhibitor with antiangiogenic and antiproliferative activity. The aim of the present study was to assess the efficacy and safety of sorafenib in patients with HER2‑negative ABC by performing a meta‑analysis. A literature search was applied to databases, including PubMed, EMBASE, the Cochrane Library Databases, American Society of Clinical Oncology and the European Society for Medical Oncology, with the search terms ‘advanced breast cancer’ and ‘sorafenib’ and relevant studies were selected for analysis. The data extracted from the selected studies included progression‑free survival (PFS), time to progression (TTP), overall survival (OS) and overall response rate (ORR). Major adverse events (AEs) were also analyzed. A total of four randomized controlled trials containing 844 cases were identified. Combined results revealed that when compared with chemotherapy (or with anti‑hormone receptor therapy) alone, sorafenib‑based therapy significantly increased the PFS [hazard ratio (HR), 0.78; 95% confidence interval (CI), 0.54‑1.02] and TTP (HR, 0.74; 95% CI, 0.50‑0.97), but not the OS (HR, 0.95; 95% CI, 0.75‑1.15) and ORR (relative risk, 1.19; 95% CI, 1.01‑1.39). In addition, the incidence of grade 3/4 AEs, including hand‑foot skin syndrome, anemia, fatigue, rash and stomatitis, were significantly increased in patients that received sorafenib‑based therapy. Therefore, the results from the current meta‑analysis indicated that sorafenib‑based therapy improved the PFS and TTP in patients with HER2‑negative ABC, but not the OS and ORR. In addition, combination treatment was associated with increased toxicities and frequently required dose reductions.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ; Panel members. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
3	Adnane L, Trail PA, Taylor I and Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407:597–612. 2006. View Article : Google Scholar : PubMed/NCBI
4	Wilhelm S, Carter C, Lynch M, et al: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
5	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar
6	Yu C, Bruzek LM, Meng XW, et al: The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 24:6861–6869. 2005. View Article : Google Scholar : PubMed/NCBI
7	Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140. 2008. View Article : Google Scholar : PubMed/NCBI
8	Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
9	Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. New Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
10	Mariani G, Burdaeva O, Roman L, et al: A double-blind, randomized phase lib study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with docetaxel and/or letrozole in patients with metastatic breast cancer (MBC): FM-B07-01 Trial. Eur J Cancer. 47:102011. View Article : Google Scholar
11	Baselga J, Segalla JG, Roché H, et al: Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol. 30:1484–1491. 2012. View Article : Google Scholar : PubMed/NCBI
12	Gradishar WJ, Kaklamani V, Sahoo TP, et al: A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer. 49:312–322. 2013. View Article : Google Scholar
13	Schwartzberg LS, Tauer KW, Hermann RC, et al: Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res. 19:2745–2754. 2013. View Article : Google Scholar
14	Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar
15	Moreno-Aspitia A, Morton RF, Hillman DW, et al: Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 27:11–15. 2009. View Article : Google Scholar
16	Bianchi G, Loibl S, Zamagni C, et al: Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 20:616–624. 2009. View Article : Google Scholar : PubMed/NCBI
17	Isaacs C, Herbolsheimer P, Liu MC, et al: Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res Treat. 125:137–143. 2011. View Article : Google Scholar : PubMed/NCBI
18	Spigel DR, Hainsworth JD, Burris HA 3rd, et al: A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. Clin Adv Hematol Oncol. 9:280–286. 2011.PubMed/NCBI
19	Lyons JF, Wilhelm S, Hibner B and Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer. 8:219–225. 2001. View Article : Google Scholar : PubMed/NCBI
20	Tanne JH: FDA cancels approval for bevacizumab in advanced breast cancer. BMJ. 343:d76842011. View Article : Google Scholar : PubMed/NCBI
21	Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
22	Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 28:3239–3247. 2010. View Article : Google Scholar : PubMed/NCBI
23	Miles D, Harbeck N, Escudier B, et al: Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol. 29:83–88. 2011. View Article : Google Scholar : PubMed/NCBI
24	Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
25	Elting J, Bigwood D, Brown-Shimer S, et al: Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma. Proc Amer Assoc Cancer Res. 47:683–684. 2006.
26	Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006. View Article : Google Scholar : PubMed/NCBI
27	Jubb AM, Oates AJ, Holden S and Koeppen H: Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer. 6:626–635. 2006. View Article : Google Scholar : PubMed/NCBI